Halozyme Advances Trial of Absorption Agent
Posted on: Wednesday, 25 January 2006, 15:01 CST
San Diego-based biopharmaceutical company Halozyme Therapeutics has completed patient enrollment in a dose-response trial of its subcutaneous hydration product used for the dispersement of drugs around the body.
The company is testing Hylenex, a liquid injectable formulation that includes the active pharmaceutical ingredient recombinant human hyaluronidase (rHuPH20). Hylenex was approved by the FDA for use as a spreading agent to increase the absorption and dispersion of other injected drugs late last year.
Subcutaneous hydration is the introduction of fluids under the skin to replace inadequate intake or excessive loss of water and electrolytes during illness or operation.
The study is designed to determine the subcutaneous infusion flow rate of lactated Ringer's solution with and without Hylenex, assess the subcutaneous infusion flow rate dose response to Hylenex over one order of magnitude of dose, and assess safety and tolerability.
Lactated Ringer's solution is a widely used fluid for intravenous rehydration. At is composed of boiled distilled water containing sodium chloride, potassium chloride, and calcium chloride in the same concentrations as found in bodily fluids.
The double-blind, placebo-controlled study has reached its target enrollment of 50 evaluable subjects. Results are expected to be presented in February this year.
Source: Datamonitor
Related Articles
- New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
- SciClone's SCV-07 Inhibits Melanoma Tumor Growth in Animal Model Study
- BioGeneriX and Neose Technologies Trial Neutropenia Drug
- BioGeneriX and Neose Announce Initiation of 2nd Phase I Clinical Trial of GlycoPEG-GCSF
- Updated Interim Long-Term Follow-Up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients With Immune Platelet Disorder
- Coley Pharmaceutical Group Announces Data From Clinical Study of ACTILON(TM) for Hepatitis C
- Coley Pharmaceutical Group Presents Data From Clinical Study of ACTILON(TM) for Hepatitis C at the European Association for the Study of the Liver Meeting
- Interim Long-Term Follow-Up Data Show AMG 531 Increases Platelets in Patients With Immune Thrombocytopenic Purpura
- Novartis Investigational Drug ICL670 Demonstrates Positive Results in Treating Chronic Iron Overload, a Potentially Life-Threatening Condition
- The Management of Nausea and Vomiting in Palliative Care
 |
 |
User Comments (0)
RSS Feeds